Royce & Associates LP Sells 4,252 Shares of TransMedics Group, Inc. $TMDX

Royce & Associates LP trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 1.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 243,149 shares of the company’s stock after selling 4,252 shares during the quarter. Royce & Associates LP’s holdings in TransMedics Group were worth $27,281,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of TMDX. Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after acquiring an additional 206 shares during the last quarter. Salomon & Ludwin LLC bought a new stake in shares of TransMedics Group during the third quarter worth $28,000. Optiver Holding B.V. increased its stake in shares of TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after buying an additional 191 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of TransMedics Group in the second quarter valued at about $48,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in TransMedics Group during the 3rd quarter worth about $40,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

TMDX opened at $145.26 on Monday. The stock has a market cap of $4.98 billion, a P/E ratio of 29.64 and a beta of 1.98. TransMedics Group, Inc. has a 12 month low of $62.07 and a 12 month high of $156.00. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. The company has a fifty day simple moving average of $133.80 and a 200 day simple moving average of $126.37.

Analysts Set New Price Targets

TMDX has been the subject of a number of research analyst reports. Needham & Company LLC boosted their target price on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Piper Sandler boosted their price objective on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Oppenheimer raised their price target on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, Morgan Stanley raised their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $150.67.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director owned 12,134 shares in the company, valued at $1,682,257.76. The trade was a 29.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.